Who is sponsoring NCT04907955?

NCT04907955 is sponsored by Dar Al Shifa Hospital.

What drugs are being tested in NCT04907955?

Interventions in NCT04907955: phacoemulsification with implantation of presbyopia correcting IOL.

What condition does NCT04907955 study?

NCT04907955 studies Loss of Visual Contrast Sensitivity, Near Vision, Visual Impairment.

Is NCT04907955 still recruiting?

NCT04907955 is currently completed. Last updated 1 June 2021.

Last reviewed 2021-06-01 · How we verify

NCT04907955

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Visual Performance Following Implantation of Presbyopia Correcting IOLs

Completed NA Last updated 1 June 2021

What this trial tests

NA trial testing phacoemulsification with implantation of presbyopia correcting IOL in Loss of Visual Contrast Sensitivity in 50 participants. Completed in 30 May 2020.

Timeline

1 June 2019

Primary endpoint
30 May 2020

30 May 2020

Quick facts

Lead sponsor	Dar Al Shifa Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	1 June 2019
Primary completion	30 May 2020
Estimated completion	30 May 2020
Sites	1 location across Kuwait

Drugs / interventions tested

phacoemulsification with implantation of presbyopia correcting IOL

Conditions studied

Loss of Visual Contrast Sensitivity — all drugs for Loss of Visual Contrast Sensitivity →
Near Vision — all drugs for Near Vision →
Visual Impairment — all drugs for Visual Impairment →

Sponsor

Dar Al Shifa Hospital

Who can join

Eligibility, any sex, with Loss of Visual Contrast Sensitivity or Near Vision. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the current study was to compare the visual performance after bilateral implantation of the Panoptix IOL , or the AT LISA IOL or Tecnis Symfony IOL . The focus was on intermediate vision, defocus curves, and contrast sensitivity.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants with presbyopia.
Zamora-de La Cruz D, Bartlett J, Gutierrez M, Ng SM. · · 2023 · cited 20× · PMID 36705482 · DOI 10.1002/14651858.cd012648.pub3
Visual performance following implantation of presbyopia correcting intraocular lenses.
Torky MA, Nokrashy AE, Metwally H, Abdelhameed AG. · · 2025 · cited 15× · PMID 35941184 · DOI 10.1038/s41433-022-02188-y

Verify or expand the search:

Other Dar Al Shifa Hospital trials

Trials by the same sponsor.

NCT04904874 — Intense Pulsed Light Therapy in Meibomian Gland Dysfunction · NA · unknown
NCT04904887 — Clinical Outcomes With a New Monofocal IOL Enhanced for Intermediate Vision · NA · unknown
NCT03288116 — Objective and Subjective Diagnostic Parameters in the Fellow Eye of Unilateral Keratoconus · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04907955 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dar Al Shifa Hospital
Last refreshed: 1 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04907955.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing